Kathleen N. Moore, MD, MS

Kathleen N. Moore, MD, MS, is an associate director of clinical research at the Stephenson Cancer Center, the director of the Oklahoma TSET Phase I Program, and a professor in the Section of Gynecologic Oncology at Oklahoma University (OU) College of Medicine, OU Health.

Articles

Dr Moore on the 2024 FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer

February 10th 2025

Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.

Dr Moore on the Relationship Between Biomarker Expression and Efficacy With ADCs in Ovarian Cancer

February 1st 2025

Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer.

Dr Moore on AEs Associated With ADC Treatment in Gynecologic Cancers

November 19th 2024

Kathleen N. Moore, MD, MS, discusses adverse effects associated with the use of antibody-drug conjugates for the treatment of gynecologic cancers.

Dr Moore on the Phase 1/2 Study Investigating Ubamatamab in Ovarian Cancer

August 21st 2023

Kathleen N. Moore, MD, MS, discusses the eligibility criteria for the ongoing, first-in-human, phase 1/2 study of ubamatamab, a MUC16- and CD3-targeted bispecific antibody, alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Dr. Moore on BCMA-Mutation Testing in Ovarian Cancer

February 23rd 2022

Kathleen Moore, MD, discusses current standard of care in treating ovarian cancer.

Dr. Moore on the Impact of the SOLO-1 Trial in Ovarian Cancer

March 18th 2019

Kathleen N. Moore, MD, associate director for clinical research, gynecologic oncologist at The Stephenson Cancer Center, The University of Oklahoma, explores the impact of the SOLO-1 trial in the field of ovarian cancer, in particular, the benefits olaparib provides and the light it shines on the importance of using genetic testing to inform treatment decisions.

Dr. Moore on Challenges With Immunotherapy in Ovarian Cancer

March 16th 2018

Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses challenges with immunotherapy agents in the treatment of patients with ovarian cancer.

Dr. Moore Discusses Combinations in Ovarian Cancer

February 23rd 2018

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations in the treatment of patients with ovarian cancer.

Dr. Moore on Immunotherapy and PARP Combinations in BRCA-Mutated Ovarian Cancer

February 10th 2018

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations of immunotherapy with PARP inhibitors for patients with BRCA-mutated ovarian cancer.

x